Palisade Bio Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
PALI Nasdaq 8731 https://palisadebio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Palisade Bio Inc

Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach - Apr 23rd, 2024 12:30 pm
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool - Apr 16th, 2024 12:30 pm
Palisade Bio to Participate in the Virtual Investor Lunch Break Event - Apr 11th, 2024 1:15 pm
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™ - Apr 10th, 2024 12:15 pm
Palisade Bio Announces 1-for-15 Reverse Stock Split - Apr 3rd, 2024 9:30 pm
Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update - Mar 27th, 2024 12:00 pm
Palisade Bio to Present at Digestive Disease Week (DDW) 2024 - Feb 15th, 2024 1:35 pm
Palisade Bio Provides Corporate Update and Reiterates Guidance - Feb 13th, 2024 1:35 pm
Correction Notice of Palisade Bio’s Press Release Announcing the Appointment of Clinical Advisory Board Members - Feb 8th, 2024 7:40 pm
Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders - Feb 8th, 2024 1:05 pm
Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 Million - Jan 30th, 2024 2:25 pm
Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn’s & Colitis Congress - Jan 29th, 2024 1:05 pm
Palisade Bio Selected for Poster Presentation at the 2024 Crohn’s & Colitis Congress - Jan 9th, 2024 1:00 pm
Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn’s and Colitis Foundation for Development of PALI-2108 - Dec 28th, 2023 1:00 pm
Palisade Bio Reports Third Quarter 2023 Financial Results and Provides Business Outlook - Nov 10th, 2023 1:05 pm
Palisade Bio to Participate at the Virtual Investor Ask the CEO Conference - Oct 11th, 2023 1:05 pm
Insider Buying: John Finley Acquires 15,000 Shares of Palisade Bio Inc - Sep 14th, 2023 11:13 pm
Palisade Bio Announces Closing of $2 Million Registered Direct Offering Priced At Market Under Nasdaq Rules - Sep 11th, 2023 8:01 pm
Palisade Bio Appoints GI Clinical Expert and Biotech Entrepreneur Mitchell Jones, M.D., Ph.D. as Chief Medical Officer - Sep 11th, 2023 12:35 pm
Palisade Bio Announces $2 Million Registered Direct Offering of Common Stock Priced At Market Under Nasdaq Rules - Sep 7th, 2023 12:30 pm